The utility of M30 and M65 antigen concentration levels for predicting degree of hepatic injury in patients with chronic hepatitis B infection

Background and Aims: We aimed to determine the utility of M30 and M65 antigen concentration levels for predicting hepatic injury in chronic hepatitis B disease. Materials and Methods: This study compared concentration levels of M30 and M65 antigens between patients with hepatitis B e-antigen negative chronic hepatitis B and healthy subjects. Furthermore, the correlations between either M30 or M65 antigen levels and aspartate aminotransferase, alanine aminotransferase, HBV-DNA, histological activity index and fibrosis were evaluated in the patient group. Results: A total of 81 subjects were included in the study; 50 patients with HBeAg negative chronic hepatitis B and 31 healthy subjects. The concentration of the M30 antigen was significantly higher in the chronic hepatitis B patient group than in the healthy subject group (p 0.05). Correlation analysis performed in the patient group revealed a significant correlation between M30 antigen concentration levels and aspartate aminotransferase levels (r: 0.207, p

Kronik hepatit B enfeksiyonununda hepatik hasar düzeyinin öngörülmesinde M30 ve M65 antijen düzeylerinin etkinliği

Giriş ve Amaç: Tüm hepatit türlerinde inflamatuvar olay nekroz ve apopitozu içeren farklı mekanizmalar ile hepatosit ölümüne sebep olur. M30-antijen apoptozis esnasında kaspazlar tarafından parçalanmış CK18 düzeylerini ölçmede, M65-antijen ise nekroza giden hücrelerden salgılanan total CK18 düzeylerini ölçmede kullanılır. Bu iki marker’ın kronik hepatit B enfeksiyonunda kullanımı ile ilgili sınırlı sayıda çalışma mevcuttur. Biz bu çalışmada M30 ve M65 antijen düzeylerinin, kronik hepatit B hastalığında karaciğer hasarını göstermede kullanılabilir olup olmadığını göstermeyi amaçladık. Gereç ve Yöntem: Bu çalışmada, Katip Çelebi Üniversitesi, İzmir Atatürk Eğitim ve Araştırma Hastanesi, Gastroenteroloji polikliniğine başvuran kronik hepatit B enfeksiyonlu hastalar ve sağlıklı kontrol grubunda, M30 ve M65 antijen düzeyleri ölçüldü ve çalışma sonunda elde edilen veriler karşılaştırıldı. Kronik aktif hepatit B enfeksiyonlu hastalarda ve sağlıklı kontrol grubunda M30 ve M65 antijen düzeyleri karşılaştırıldı. Ayrıca hasta grupta M30-M65 düzeyleri ile aspartat aminotransferaz, alanin aminotransferaz, hepatit B virus DNA, histoloji aktivite indeksi ve fibrozis düzeyleri arasındaki ilişki değerlendirildi. Bulgular: Çalışmaya 50 kronik aktif hepatit B hastası ve 31 sağlıklı kontrol olmak üzere toplam 81 hasta alındı. Hepatit B hasta grubunda M30-antijen düzeyi kontrol grubuna göre anlamlı düzeyde yüksek bulundu (p0.05). Hasta grupta yapılan korelasyon analizinde M30-antijen ile aspartat aminotransferaz arasında (r:0.207, p

Kaynakça

Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-29.

Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-75.

Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005;25:40-7.

Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507- 39.

Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007;13:4865-72.

Lapierre P, Beland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007;149:107-13.

Day CP. Apoptosis in alcoholic hepatitis: a novel therapeutic target? J Hepatol 2001;34:330-3.

Assuncao Guimaraes C and Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. Eur J Biochem 2004;271:1638-50.

Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984;142:67- 77.

Öktem S, Özhan MH, Özol D. The importance of apoptosis. Toraks Dergisi 2001;2:91-5.

CB T. Apoptosis. Lippincott- Raven Publishers, 1999.

Ulukaya E, Yilmaztepe A, Akgoz S, et al. The levels of caspasecleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007;56:399-404.

Smith F. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003;4:347-64.

Quinlan RA, Schiller DL, Hatzfeld M, et al. Patterns of expression and organization of cytokeratin intermediate filaments. Ann N Y Acad Sci 1985;455:282-306.

Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.

Kronenberger B, Wagner M, Herrmann E, et al. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat 2005;12:307-14.

Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078- 87.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-98.

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.

McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S45-55.

Kronenberger B, Zeuzem S, Sarrazin C, et al. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir Ther 2007;12:779-87.

Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009;361:1570-83.

Farnik H, Lange CM, Hofmann WP, et al Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. J Clin Virol 2011;52:204-9.

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008;57:500-6.

Yilmaz Y, Dolar E, Ulukaya E, et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med Sci Monit 2009;15:CR189-93.

Tabuchi M, Tomioka K, Kawakami T, et al. Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol (Tokyo) 2010;56:271-8.

Kaynak Göster